Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein, which orchestrates the body's antiviral responses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom. Show more

Location: Mailpoint 810, South Block, Southampton, SO16 6YD, United Kingdom | Website: https://www.synairgen.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

220.5K

52 Wk Range

$0.00 - $0.07

Previous Close

$0.00

Open

$0.00

Volume

N/A

Day Range

$0.00 - $0.00

Enterprise Value

-11.36M

Cash

4.554M

Avg Qtr Burn

-11.96M

Insider Ownership

0.57%

Institutional Own.

87.22%

Qtr Updated

12/31/24